PAIOF (Paion AG) Debt-to-Equity: -6.93 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAIOF Paion AG PAIOF
10 GF Score
Price $0.07
View Full Analysis

What is Paion AG Debt-to-Equity?

Paion AG PAIOF 10 Debt-to-Equity is -6.93 as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

Paion AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.00 Mil. Paion AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $20.02 Mil. Paion AG's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-3.32 Mil. Paion AG's debt to equity for the quarter that ended in Jun. 2023 was -6.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Paion AG's Debt-to-Equity or its related term are showing as below:

PAIOF's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Paion AG  (OTCPK:PAIOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Paion AG Debt-to-Equity Related Terms

Paion AG Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Paion AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Debt-to-Equity Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.30 0.00 2.89 3.08

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 2.89 1.21 3.08 -6.93

PAIOF vs ZTS, NBIX, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paion AG Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Paion AG's Debt-to-Equity falls into.


PAIOF
10GF Score
Paion AG PAIOF
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Paion AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.517 + 20.042) / 7.007
=3.08

Paion AG's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.004 + 20.018) / -3.322
=-6.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -6.93 mean?
Paion AG (PAIOF) has a Debt-to-Equity of -6.93 as of Jun. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paion AG and its competitors.
Is Paion AG's Debt-to-Equity too high?
Paion AG's current Debt-to-Equity is -6.93. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Debt-to-Equity compare to ZTS and NBIX?
Paion AG's Debt-to-Equity of -6.93 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current Debt-to-Equity is -6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Debt-to-Equity of -6.93. The current Debt-to-Equity is -6.93. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Paion AG (PAIOF), the current Debt-to-Equity is -6.93 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price